Keryx Biopharmaceuticals Inc
KERX
KERX was delisted on the 12th of December, 2018.
147 hedge funds and large institutions have $1.08B invested in Keryx Biopharmaceuticals Inc in 2014 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 43 increasing their positions, 48 reducing their positions, and 17 closing their positions.
53% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 17
16% more call options, than puts
Call options by funds: $27.6M | Put options by funds: $23.8M
5% more funds holding
Funds holding: 140 → 147 (+7)
4% more capital invested
Capital invested by funds: $1.04B → $1.08B (+$40.2M)
10% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 48
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$8.65M |
| 2 |
PC
PointState Capital
New York
|
+$7.75M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$6.74M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$6.5M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$5.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Allianz Asset Management
Munich,
Germany
|
-$17.5M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$7.75M |
| 3 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
-$6.73M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$5.54M |
| 5 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
-$5.49M |
KERX Hedge Fund Activity: Q4 2014 in Review
147 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q4 2014, worth a combined $1.08B — up 3.9% from $1.04B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new KERX positions and 17 closed out — a net gain of 9 holders — while 43 added to existing stakes and 48 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $8.65M. The largest seller was Allianz Asset Management, cutting an estimated $17.5M.
- 147 institutional investors held Keryx Biopharmaceuticals Inc (KERX) as of Q4 2014, up from 140 in Q3 2014.
- Funds reported $1.08B of Keryx Biopharmaceuticals Inc stock for Q4 2014, up 3.9% quarter-over-quarter.
- 26 funds opened new Keryx Biopharmaceuticals Inc positions in Q4 2014 and 17 closed out, a net change of +9 holders.
- The largest Keryx Biopharmaceuticals Inc buyer in Q4 2014 was JP Morgan Chase, an estimated $8.65M added.
- The largest Keryx Biopharmaceuticals Inc seller in Q4 2014 was Allianz Asset Management, an estimated $17.5M sold.
Based on aggregated 13F filings for Q4 2014.